title: [Malignant melanoma].
authors.affiliation: Interdisziplinäres Onkologisches Zentrum München. m.schmid-wendtner@ioz-muenchen.de
authors.forename: M
authors.initials: M
authors.lastname: Schmid-Wendtner
authors.forename: C-M
authors.initials: CM
authors.lastname: Wendtner
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D018450:Disease Progression; D018572:Disease-Free Survival; D042241:Early Diagnosis; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D000074324:Ipilimumab; D008207:Lymphatic Metastasis / Q000473:pathology; D008545:Melanoma / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008940:Mitotic Index; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib